Cosmetic composition and method
US6713074B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Jun 29, 2001 |
| Grant date | Mar 30, 2004 |
| Priority date | — |
| Expiry date | Jun 29, 2021 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2800/782
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The cosmetic topical formulation of this invention is directed toward diminishing skin wrinkling, fine line, improving skin tone, and combinations thereof. Preferably, the topical formulation contains a matrix metalloproteinase inhibitor, MMPI, and advantageously includes a natural estrogen, e.g., a true estrogen compound, such as 17-beta estradiol, or an estrogen-like steroid, (such as various phytoestrogens found in herbal preparations), as opposed to a synthetic estrogen. Other forms of the cosmetic topical formulation of this invention include combinations of synthetic estrogen and MMP inhibitor. Exemplary synthetic estrogens include, but are not limited to, ethinyl estradiol and clomiphine citrate. The cosmetic topical formulation is safe and effective diminishing wrinkling, and improving skin tone. Certain compositions of this invention are useful for minimizing photodamage to skin, while in other embodiments, the composition according to this invention is useful to prevent or minimize the adverse effects on skin induced by cigarette smoking.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.